Biocorp Production SA
PAR:ALCOR
Intrinsic Value
BIOCORP Production SA is a technology-driven manufacturing medical company. [ Read More ]
The intrinsic value of one
ALCOR
stock under the Base Case scenario is
15.19
EUR.
Compared to the current market price of 35.1 EUR,
Biocorp Production SA
is
Overvalued by 57%.
ALCOR's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
ALCOR or that its price is influenced by factors unrelated to fundamentals.
Biocorp Production SA's market capitalization is 154.4m EUR.
ALCOR stock price is 35.1 EUR.
ALCOR stock (15.19 EUR) is 57% less than its price (35.1 EUR).
ALCOR stock (16.1 EUR) is 54% less than its price (35.1 EUR). Open Relative Valuation
ALCOR has upside potential of 1% compared to the average analyst price target.
Open Wall St Estimates
ALCOR has positive Net Debt. This means that the company has more debt (5m EUR) than cash and short-term investments (3m EUR).
ALCOR's Revenue has grown by 14% over the past 12 months.
ALCOR's long-term assets (13m EUR) exceed its long-term liabilties (10m EUR).
ALCOR's short-term assets (9m EUR) exceed its short-term liabilties (5m EUR).
ALCOR's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -6%.
ALCOR's ROE (Return on Equity) has significantly increased in the last 3 years from -87% to -23%, and is approaching profitability.
ALCOR's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -27% to -6%, and is approaching profitability.
ALCOR's D/E (Debt to Equity) is equal to 1.95.
ALCOR's Revenue is forecast to grow at a rate of 37% per year over the next 3 years.
ALCOR has negative Net Income for the last twelve months.
ALCOR has negative Operating Income for the last twelve months.
ALCOR's ROE (Return on Equity) for the past 12 months is negative and is equal to -23%.
ALCOR has positive Gross Profit for the last twelve months.
ALCOR has negative three-year average ROIC (Return on Invested Capital): -8%. The company is not efficient at using invested capital to generate operating income.
ALCOR has negative Free Cash Flow for the last twelve months.
ALCOR has negative three-year average ROE (Return on Equity): -26%. The company is not efficient at transforming stockholders' equity into net income.
ALCOR's Altman Z-Score is very high and is equal to 6.5.
Valuation Backtest
Biocorp Production SA
Run backtest to discover the historical profit from buying and selling
ALCOR
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Biocorp Production SA
Balance Sheet Decomposition
Biocorp Production SA
| Current Assets | 8.7m |
| Cash & Short-Term Investments | 2.7m |
| Receivables | 4m |
| Other Current Assets | 2.1m |
| Non-Current Assets | 3.9m |
| Long-Term Investments | 427.4k |
| PP&E | 3.4m |
| Intangibles | 40.1k |
| Current Liabilities | 5.3m |
| Accounts Payable | 1.2m |
| Accrued Liabilities | 1.4m |
| Short-Term Debt | 14.9k |
| Other Current Liabilities | 2.7m |
| Non-Current Liabilities | 4.8m |
| Long-Term Debt | 4.8m |
| Other Non-Current Liabilities | 310 |
Earnings Waterfall
Biocorp Production SA
|
Revenue
|
11.7m
EUR
|
|
Cost of Revenue
|
-1m
EUR
|
|
Gross Profit
|
10.6m
EUR
|
|
Operating Expenses
|
-11.4m
EUR
|
|
Operating Income
|
-732.1k
EUR
|
|
Other Expenses
|
80.9k
EUR
|
|
Net Income
|
-651.2k
EUR
|
Free Cash Flow Analysis
Biocorp Production SA
ALCOR Profitability Score
Profitability Due Diligence
Biocorp Production SA's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
Score
Biocorp Production SA's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
ALCOR Solvency Score
Solvency Due Diligence
Biocorp Production SA's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Score
Biocorp Production SA's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ALCOR Price Targets Summary
Biocorp Production SA
According to Wall Street analysts, the average 1-year price target for
ALCOR
is 35.3 EUR
.
Shareholder Return
ALCOR Price
Biocorp Production SA
| Average Annual Return | 55.15% |
| Standard Deviation of Annual Returns | 68.53% |
| Max Drawdown | -65% |
| Market Capitalization | 154.4m EUR |
| Shares Outstanding | 4 400 245 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Biocorp Production SA
Country
Industry
Market Cap
Dividend Yield
Description
BIOCORP Production SA is a technology-driven manufacturing medical company. The company is headquartered in Issoire, Auvergne-Rhone-Alpes and currently employs 74 full-time employees. The company went IPO on 2015-07-10.
Contact
IPO
Employees
Officers
The intrinsic value of one
ALCOR
stock under the Base Case scenario is
15.19
EUR.
Compared to the current market price of 35.1 EUR,
Biocorp Production SA
is
Overvalued by 57%.
You don't have any saved screeners yet
